Skip to main content

Adaptive Biotechnologies

Adaptive Biotechnologies Corporation is an American biotechnology enterprise developing immune-sequencing diagnostics for disease detection. The company structures its operational focus across two primary areas: Minimal Residual Disease (MRD) testing and Immune Medicine discovery. Its core commercial product is clonoSEQ, an FDA-cleared diagnostic for tracking residual disease in blood cancers, alongside immuno-sequencing research tools. Primary revenue is derived from clinical diagnostic testing fees alongside biopharmaceutical research collaboration and licensing payments. Adaptive Biotechnologies holds a leading market position in adaptive immune system decoding and clinical MRD testing. The company is headquartered in Seattle, Washington, and its shares trade on the Nasdaq Global Select Market.

8 of the funds FundTelligence covers report a position in Adaptive Biotechnologies.

Legal name
Adaptive Biotechnologies Corp
Sector
Health Care
Country
United States
Funds holding it
8
Exposure themes
Genomics & Profiling, Immune Repertoire Profiling, Precision Medicine & Genomics

Funds holding Adaptive Biotechnologies

Loading...